Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Long-Acting Injectable Buprenorphine: Uptake Was Rapid But Uneven, 2021-24

AI Summary
  • Rapid but uneven uptake: 41,488 of 2,266,202 episodes (1.83 per cent), with substantial state variation.
  • By 2024 Medicaid was the primary payer, covering 71 per cent of long-acting injectable buprenorphine episodes.
  • Most prescriptions were written by advanced practice clinicians, primarily nurse practitioners, comprising 62 per cent of long-acting injectable episodes.
Summarise with AI (MRCPsych/FRANZCP)

Health Aff (Millwood). 2026 Jul;45(7):819-825. doi: 10.1377/hlthaff.2025.01584.

ABSTRACT

We analyzed nationwide IQVIA pharmacy buprenorphine prescription episodes to characterize patterns, prescribers, and payers of long-acting injectable buprenorphine during the period 2021-24. Among 2,266,202 episodes, 41,488 (1.83 percent) were identified as being initiated with long-acting injectables, varying greatly across states. By 2024, Medicaid emerged as the most likely payer (71 percent of episodes), and most long-acting injectable episodes were prescribed by advanced practice clinicians such as nurse practitioners (62 percent).

PMID:42413053 | DOI:10.1377/hlthaff.2025.01584

Document this CPD

Share Evidence Blueprint

QR Code

Search Google Scholar

Save as PDF

close chatgpt icon
ChatGPT

Enter your request.

Psychiatry AI: Real-Time AI Scoping Review